查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1742507

腎臟癌症治療藥市場:癌症類別，各治療法，各類藥物，各給藥途徑，各流通管道，各地區，機會，預測，2018年～2032年

Kidney Cancer Drugs Market Assessment, By Cancer Type, By Therapy, By Drug Class, By Route of Administration, By Distribution Channel, Region, Opportunities and Forecast, 2018-2032F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 245 Pages | 商品交期: 3-5個工作天內

價格

全球腎癌藥物市場規模預計將從2024年的70.2億美元增至2032年的110.2億美元，在2025-2032年的預測期內，複合年增長率為5.80%。受人口老化、治療方案的進步以及臨床因素等因素的共同作用，全球腎癌藥物市場正在經歷快速成長。根據美國癌症協會估計，2024年將有約81,610人（52,380名男性和29,230名女性）新診斷出患有腎癌，約14,390人（9,450名男性和4,940名女性）將死於該疾病。

腎癌藥物市場的成長得益於幾個關鍵推動因素。首先，隨著全球人口老化和生活方式的改變，腎癌發生率不斷上升，需要治療的患者數量也不斷增加。最值得注意的是，實證治療方案已顯著改善，隨著免疫療法和標靶療法成為最常用的治療方案，患者的治療結果也發生了變化。主要趨勢之一是轉向高效的聯合療法，這些療法已被接受為標準治療的一線治療方案。

此外，在研發 (R&D) 方面的大量投資持續成長，催生了一系列創新藥物，例如新型 HIF-2a 抑制劑。此外，口服療法易於給藥，人們也越來越關注基於分子診斷的個人化治療，這些因素正在推動市場發展，從而提高治療效果並鼓勵患者依從性。例如，2025年2月，Telix Pharmaceuticals Limited宣布，FDA已批准TLX250-CDx用於治療透明細胞腎細胞癌（ccRCC）的生物製品許可申請（BLA），並將其列入優先審查。

本報告提供全球腎臟癌症治療藥市場相關調查，提供市場概要，以及癌症類別，各治療法，各類藥物，各給藥途徑，各流通管道，各地區趨勢，及加入此市場的主要企業簡介等資訊。

目錄

第1章 計劃的範圍和定義

第2章 調查手法

第3章 美國的關稅的影響

第4章 摘要整理

第5章 全球腎臟癌症治療藥市場預測，2018年～2032年

  • 市場規模分析與預測
  • 市場佔有率分析與預測
    • 癌症類別
      • 腎細胞癌症(RCC)
      • 轉移表皮癌症(TCC)
      • 威爾姆氏腫瘤(腎芽腫)
      • 其他
    • 各治療法
      • 標靶治療
      • 免疫療法
      • 化療
      • 其他
    • 各類藥物
      • 抗血管新生
      • 單株抗體
      • mTOR抑制劑
      • 白細胞介素
      • 其他
    • 各給藥途徑
      • 口服
      • 靜脈內
      • 皮下
    • 各流通管道
      • 醫院
      • 專門藥局及零售藥局
      • 其他
    • 各地區
      • 北美
      • 歐洲
      • 亞太地區
      • 南美
      • 中東·非洲
    • 各企業市場佔有率分析(前五名公司以及其他- 各金額，2024年)
  • 2024年的市場地圖分析

第6章 北美的腎臟癌症治療藥市場預測，2018年～2032年

  • 市場規模分析與預測
  • 市場佔有率分析與預測
  • 各國市場評估
    • 美國
    • 加拿大
    • 墨西哥

第7章 歐洲的腎臟癌症治療藥市場預測，2018年～2032年

  • 德國
  • 法國
  • 義大利
  • 英國
  • 俄羅斯
  • 荷蘭
  • 西班牙
  • 土耳其
  • 波蘭

第8章 亞太地區的腎臟癌症治療藥市場預測，2018年～2032年

  • 印度
  • 中國
  • 日本
  • 澳洲
  • 越南
  • 韓國
  • 印尼
  • 菲律賓

第9章 南美的腎臟癌症治療藥市場預測，2018年～2032年

  • 巴西
  • 阿根廷

第10章 中東·非洲的腎臟癌症治療藥市場預測，2018年～2032年

  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第11章 需求供給分析

第12章 價值鏈分析

第13章 波特的五力分析

第14章 大環境分析

第15章 價格分析

第16章 市場動態

  • 市場促進因素
  • 市場課題

第17章 市場趨勢與發展

第18章 法律規範

  • 臨床試驗
  • 法規當局的認證

第19章 專利的形勢

第20章 案例研究

第21章 競爭情形

  • 前五名市場領導的競爭矩陣
  • 前五名參與企業的SWOT分析
  • 前10名市場主要企業的形勢
    • Amgen Inc.
    • Pfizer Inc.
    • Novartis AG
    • Cipla Ltd.
    • F. Hoffmann-La Roche AG
    • Bayer AG
    • Exelixis, Inc.
    • Bristol-Myers Squibb Company
    • Merck & Co., Inc.
    • UroGen Pharma Ltd.

第22章 策略性建議

第23章 關於調查公司·免責聲明

Product Code: MX13253

Global kidney cancer drugs market is projected to witness a CAGR of 5.80% during the forecast period 2025-2032, growing from USD 7.02 billion in 2024 to USD 11.02 billion in 2032. The global kidney cancer drugs market experiences rapid growth, driven by a combination of aging population, advancement in therapeutic option and clinical factors. As per the American Cancer Society's estimates in 2024

around 81,610 new cases of kidney cancer (52,380 males and 29,230 females) are diagnosed and about 14,390 people (9,450 men and 4,940 women) died from this disease.

The kidney cancer drug market is seeing growth owing to several principal drivers. First, as the global population continues to age and lifestyle factors change, the incidence of kidney cancer is rising, with the number of patients in need of treatment also increasing. Most notably, the outcomes of patients have changed as evidence-based treatment options have improved significantly with the rise of immunotherapy, and targeted therapies as the most used treatment options. One of the main trends is a shift toward the use of extremely effective combination therapies, which are recognized as standard of care first line therapy.

Moreover, the extensive investment in Research and Development (R&D) is consistently evolving, resulting in a pipeline of innovative agents such as new classes of HIF-2a inhibitors. Also, with the ease of administration of oral therapies and an increased focus on individualized therapy based on molecular diagnostics, both majorly drive market development in a way that enhances the efficacy of treatment and promotes patient compliance. For instance, in February 2025, Telix Pharmaceuticals Limited declared that the FDA has approved and given priority consideration to the BLA of TLX250-CDx for the treatment of clear cell renal cell carcinoma (ccRCC).

Advancement in Diagnostic Technology

Developments in advanced diagnostic technologies are fundamentally driving growth in the global kidney cancer drugs market by creating more opportunities for early detection, better tumor characterization, and personalized treatment approaches. Advancements in imaging technologies such as AI-enriched CT/MRI and new PET-CT tracers enable the identification of smaller tumors that improve patient eligibility for systemic therapies. Additionally, liquid biopsies and genomic profiling enable the non-invasive detection of mutations and help to refine the use of targeted therapies and immunotherapy based on individual patient biomarkers. AI-enabled diagnostic platforms aim to optimize treatment selection based on prediction of drug responses on a given patient, which mitigates the burden of trial-and-error prescribing and allows for greater adoption of high-efficacy treatment regimens. Furthermore, sequential combination therapies, digitized multi-omics, and AI diagnostic capabilities will further attract patients and drive demand in new areas of precision medicine.

Additionally, leading research organizations are focusing on developing new technologies to improve the quality of care provided to the patient population. For instance, according to an article published in American Society of Clinical Oncology (ASCO) in February 2023, the Phase 3 ZIRCON trial assessed the use of Zr-DFO-girentuximab PET/CT imaging to detect and characterize clear-cell renal cell carcinoma (ccRCC).

Hospitals Holds Largest Distribution Channels of Drugs

There are various key factors contributing to the dominating position of hospitals segment in the kidney cancer drugs market. One reason is the treatment for kidney cancer may include complicated regimens in terms of dosage, handling, storage requiring special consideration, as well as requiring thorough ongoing monitoring of side effects, due to the use of immunotherapies and targeted therapies. Research suggests the complicated treatment regimen can be managed more effectively by hospital-based oncology departments with highly skilled doctors and specialty oncology pharmacists on staff as well as nursing staff. They provide a controlled setting for intravenous drug administration, administer possible drug interactions, and offer extensive patient education and support care. Moreover, the exorbitant prices of most new kidney cancer drugs most often require dispensing by hospital pharmacies, which also enjoy bulk purchasing power and established supply chains for repeated access to these potentially life-saving drugs for patients receiving intensive cancer treatment. For instance, in January 2024, Fox Chase Cancer Center invested in a new study to demonstrate that immune checkpoint inhibitor-based therapy (ICI), a form of immunotherapy, is an equally effective frontline therapy for Black and white patients with metastatic kidney cell carcinoma.

The expansion of the Asia-Pacific kidney Cancer Medication Market

The renal cancer drug market is spearheaded in the Asia-Pacific (APAC) region for many reasons, as examples, the increasing incident and prevalence of kidney cancer linked to aging and lifestyles has positively contributed to a larger patient pool. Additionally, growing investments in the healthcare infrastructure and increased public understanding have improved early detection and significant demand for newer treatments. Patients now have greater access to pricey new medicines thanks to APAC's robust economic growth, rising healthcare costs, and expanding insurance coverage. Personalized medicine, such as targeted treatments and immunotherapies, is a major focus in the region, as well as high R&D and pharma investment, propels the creation and adoption of innovative medicines, But APAC's market does come with significant challenges. The exorbitant price of new kidney cancer medicines is a major hurdle for most patients, affecting accessibility. Varying and sometimes complex regulatory approvals in different nations have the potential to slow market access for innovative drugs.

Additionally, for market expansion in Asia-Pacific region in March 2025 companies like HUTCHMED (China) Limited and Innovent Biologics,Inc. jointly announced that FRUSICA-2 phase II/III clinical trial study in China for advanced renal cell carcinoma.

Impact of U.S. Tariffs on Kidney Cancer Drugs Market

The impact from recent the recent U.S. tariffs which targeted pharmaceutical import from China and India and other major suppliers. The tariffs cause an increase in production expenses which might raise drugs prices while creating potential disruptions in the supply chains. The thin profits margin of generic drugs manufacturer would intensify because of these added expenses which could lead to decreased competition and reduced treatment options. The global pharmaceutical export market faces economic trouble because of challenging condition in Ireland and South Korea. The possibility of companies moving manufacturing operation back to the United States may create temporary drugs shortages that will affect patient worldwide by disrupting their access to treatment and negatively impacts their outcomes.

Key Players Landscape and Outlook

There is an intense competition in the kidney cancer drugs market from established pharmaceutical companies and new start-up biotech firms involved in research and development. Additionally, the kidney cancer drugs market is projected to continue to grow in part due to new advances in immunotherapy, targeted therapy and increased combination or multi-modality regimens. The focus on more effective treatments with personalization and improved safety profiles will continue to enable patient improvements and quality of life. Companies like Novartis AG and Merck & Co., Inc. are continuously working on new innovation for the renal cell treatment.

According to the news published on Clinical trials Arena in October 2024, Arcus Biosciences Inc. announced a clinical trial collaboration with AstraZeneca plc to evaluate the combination of casdatifan (AB521) and volrustomig in ccRCC patients. Casdatifan is an investigational HIF-2a inhibitor from Arcus and volrustomig is an investigational PD-1/CTLA-4 bispecific antibody from AstraZeneca.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of the U.S. Tariffs

4. Executive Summary

5. Global Kidney Cancer Drugs Market Outlook, 2018-2032F

  • 5.1. Market Size Analysis & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share Analysis & Forecast
    • 5.2.1. By Cancer Type
      • 5.2.1.1. Renal Cell Carcinoma (RCC)
      • 5.2.1.2. Transitional Cell Cancer (TCC)
      • 5.2.1.3. Wilms Tumor (Nephroblastoma)
      • 5.2.1.4. Others
    • 5.2.2. By Therapy
      • 5.2.2.1. Targeted Therapy
      • 5.2.2.2. Immunotherapy
      • 5.2.2.3. Chemotherapy
      • 5.2.2.4. Other Therapies
    • 5.2.3. By Drug Class
      • 5.2.3.1. Anti-Angiogenesis
      • 5.2.3.2. Monoclonal Antibodies
      • 5.2.3.3. mTOR Inhibitors
      • 5.2.3.4. Interleukins
      • 5.2.3.5. Other Drug Classes
    • 5.2.4. By Route of Administration
      • 5.2.4.1. Oral
      • 5.2.4.2. Intravenous
      • 5.2.4.3. Subcutaneous
    • 5.2.5. By Distribution Channel
      • 5.2.5.1. Hospital
      • 5.2.5.2. Specialty and Retail Pharmacies
      • 5.2.5.3. Others
    • 5.2.6. By Region
      • 5.2.6.1. North America
      • 5.2.6.2. Europe
      • 5.2.6.3. Asia-Pacific
      • 5.2.6.4. South America
      • 5.2.6.5. Middle East and Africa
    • 5.2.7. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
  • 5.3. Market Map Analysis, 2024
    • 5.3.1. By Cancer Type
    • 5.3.2. By Therapy
    • 5.3.3. By Drug Class
    • 5.3.4. By Route of Administration
    • 5.3.5. By Distribution Channel
    • 5.3.6. By Region

6. North America Kidney Cancer Drugs Market Outlook, 2018-2032F

  • 6.1. Market Size Analysis & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share Analysis & Forecast
    • 6.2.1. By Cancer Type
      • 6.2.1.1. Renal Cell Carcinoma (RCC)
      • 6.2.1.2. Transitional Cell Cancer (TCC)
      • 6.2.1.3. Wilms Tumor (Nephroblastoma)
      • 6.2.1.4. Others
    • 6.2.2. By Therapy
      • 6.2.2.1. Targeted Therapy
      • 6.2.2.2. Immunotherapy
      • 6.2.2.3. Chemotherapy
      • 6.2.2.4. Other Therapies
    • 6.2.3. By Drug Class
      • 6.2.3.1. Anti-Angiogenesis
      • 6.2.3.2. Monoclonal Antibodies
      • 6.2.3.3. mTOR Inhibitors
      • 6.2.3.4. Interleukins
      • 6.2.3.5. Other Drug Classes
    • 6.2.4. By Route of Administration
      • 6.2.4.1. Oral
      • 6.2.4.2. Intravenous
      • 6.2.4.3. Subcutaneous
    • 6.2.5. By Distribution Channel
      • 6.2.5.1. Hospital
      • 6.2.5.2. Specialty and Retail Pharmacies
      • 6.2.5.3. Others
    • 6.2.6. By Country Share
      • 6.2.6.1. United States
      • 6.2.6.2. Canada
      • 6.2.6.3. Mexico
  • 6.3. Country Market Assessment
    • 6.3.1. United States Kidney Cancer Drugs Market Outlook, 2018-2032F*
      • 6.3.1.1. Market Size Analysis & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share Analysis & Forecast
        • 6.3.1.2.1. By Cancer Type
          • 6.3.1.2.1.1. Renal Cell Carcinoma (RCC)
          • 6.3.1.2.1.2. Transitional Cell Cancer (TCC)
          • 6.3.1.2.1.3. Wilms Tumor (Nephroblastoma)
          • 6.3.1.2.1.4. Others
        • 6.3.1.2.2. By Therapy
          • 6.3.1.2.2.1. Targeted Therapy
          • 6.3.1.2.2.2. Immunotherapy
          • 6.3.1.2.2.3. Chemotherapy
          • 6.3.1.2.2.4. Other Therapies
        • 6.3.1.2.3. By Drug Class
          • 6.3.1.2.3.1. Anti-Angiogenesis
          • 6.3.1.2.3.2. Monoclonal Antibodies
          • 6.3.1.2.3.3. mTOR Inhibitors
          • 6.3.1.2.3.4. Interleukins
          • 6.3.1.2.3.5. Other Drug Classes
        • 6.3.1.2.4. By Route of Administration
          • 6.3.1.2.4.1. Oral
          • 6.3.1.2.4.2. Intravenous
          • 6.3.1.2.4.3. Subcutaneous
        • 6.3.1.2.5. By Distribution Channel
          • 6.3.1.2.5.1. Hospital
          • 6.3.1.2.5.2. Specialty and Retail Pharmacies
          • 6.3.1.2.5.3. Others
    • 6.3.2. Canada
    • 6.3.3. Mexico

All segments will be provided for all regions and countries covered

7. Europe Kidney Cancer Drugs Market Outlook, 2018-2032F

  • 7.1. Germany
  • 7.2. France
  • 7.3. Italy
  • 7.4. United Kingdom
  • 7.5. Russia
  • 7.6. Netherlands
  • 7.7. Spain
  • 7.8. Turkey
  • 7.9. Poland

8. Asia-Pacific Kidney Cancer Drugs Market Outlook, 2018-2032F

  • 8.1. India
  • 8.2. China
  • 8.3. Japan
  • 8.4. Australia
  • 8.5. Vietnam
  • 8.6. South Korea
  • 8.7. Indonesia
  • 8.8. Philippines

9. South America Kidney Cancer Drugs Market Outlook, 2018-2032F

  • 9.1. Brazil
  • 9.2. Argentina

10. Middle East and Africa Kidney Cancer Drugs Market Outlook, 2018-2032F

  • 10.1. Saudi Arabia
  • 10.2. UAE
  • 10.3. South Africa

11. Demand Supply Analysis

12. Value Chain Analysis

13. Porter's Five Forces Analysis

14. PESTLE Analysis

15. Pricing Analysis

16. Market Dynamics

  • 16.1. Market Drivers
  • 16.2. Market Challenges

17. Market Trends and Developments

18. Regulatory Framework

  • 18.1. Clinical Trials
  • 18.2. Regulatory Approvals

19. Patent Landscape

20. Case Studies

21. Competitive Landscape

  • 21.1. Competition Matrix of Top 5 Market Leaders
  • 21.2. SWOT Analysis for Top 5 Players
  • 21.3. Key Players Landscape for Top 10 Market Players
    • 21.3.1. Amgen Inc.
      • 21.3.1.1. Company Details
      • 21.3.1.2. Key Management Personnel
      • 21.3.1.3. Products and Services
      • 21.3.1.4. Financials (As Reported)
      • 21.3.1.5. Key Market Focus and Geographical Presence
      • 21.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
    • 21.3.2. Pfizer Inc.
    • 21.3.3. Novartis AG
    • 21.3.4. Cipla Ltd.
    • 21.3.5. F. Hoffmann-La Roche AG
    • 21.3.6. Bayer AG
    • 21.3.7. Exelixis, Inc.
    • 21.3.8. Bristol-Myers Squibb Company
    • 21.3.9. Merck & Co., Inc.
    • 21.3.10. UroGen Pharma Ltd.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

22. Strategic Recommendations

23. About Us and Disclaimer

List of Tables

  • Table 1. Competition Matrix of Top 5 Market Leaders
  • Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Kidney Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 2. Global Kidney Cancer Drugs Market Share (%), By Cancer Type, 2018-2032F
  • Figure 3. Global Kidney Cancer Drugs Market Share (%), By Therapy, 2018-2032F
  • Figure 4. Global Kidney Cancer Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 5. Global Kidney Cancer Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 6. Global Kidney Cancer Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 7. Global Kidney Cancer Drugs Market Share (%), By Region, 2018-2032F
  • Figure 8. North America Kidney Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 9. North America Kidney Cancer Drugs Market Share (%), By Cancer Type, 2018-2032F
  • Figure 10. North America Kidney Cancer Drugs Market Share (%), By Therapy, 2018-2032F
  • Figure 11. North America Kidney Cancer Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 12. North America Kidney Cancer Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 13. North America Kidney Cancer Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 14. North America Kidney Cancer Drugs Market Share (%), By Country, 2018-2032F
  • Figure 15. United States Kidney Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 16. United States Kidney Cancer Drugs Market Share (%), By Cancer Type, 2018-2032F
  • Figure 17. United States Kidney Cancer Drugs Market Share (%), By Therapy, 2018-2032F
  • Figure 18. United States Kidney Cancer Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 19. United States Kidney Cancer Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 20. United States Kidney Cancer Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 21. Canada Kidney Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 22. Canada Kidney Cancer Drugs Market Share (%), By Cancer Type, 2018-2032F
  • Figure 23. Canada Kidney Cancer Drugs Market Share (%), By Therapy, 2018-2032F
  • Figure 24. Canada Kidney Cancer Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 25. Canada Kidney Cancer Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 26. Canada Kidney Cancer Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 27. Mexico Kidney Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 28. Mexico Kidney Cancer Drugs Market Share (%), By Cancer Type, 2018-2032F
  • Figure 29. Mexico Kidney Cancer Drugs Market Share (%), By Therapy, 2018-2032F
  • Figure 30. Mexico Kidney Cancer Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 31. Mexico Kidney Cancer Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 32. Mexico Kidney Cancer Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 33. Europe Kidney Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 34. Europe Kidney Cancer Drugs Market Share (%), By Cancer Type, 2018-2032F
  • Figure 35. Europe Kidney Cancer Drugs Market Share (%), By Therapy, 2018-2032F
  • Figure 36. Europe Kidney Cancer Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 37. Europe Kidney Cancer Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 38. Europe Kidney Cancer Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 39. Europe Kidney Cancer Drugs Market Share (%), By Country, 2018-2032F
  • Figure 40. Germany Kidney Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 41. Germany Kidney Cancer Drugs Market Share (%), By Cancer Type, 2018-2032F
  • Figure 42. Germany Kidney Cancer Drugs Market Share (%), By Therapy, 2018-2032F
  • Figure 43. Germany Kidney Cancer Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 44. Germany Kidney Cancer Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 45. Germany Kidney Cancer Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 46. France Kidney Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 47. France Kidney Cancer Drugs Market Share (%), By Cancer Type, 2018-2032F
  • Figure 48. France Kidney Cancer Drugs Market Share (%), By Therapy, 2018-2032F
  • Figure 49. France Kidney Cancer Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 50. France Kidney Cancer Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 51. France Kidney Cancer Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 52. Italy Kidney Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 53. Italy Kidney Cancer Drugs Market Share (%), By Cancer Type, 2018-2032F
  • Figure 54. Italy Kidney Cancer Drugs Market Share (%), By Therapy, 2018-2032F
  • Figure 55. Italy Kidney Cancer Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 56. Italy Kidney Cancer Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 57. Italy Kidney Cancer Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 58. United Kingdom Kidney Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 59. United Kingdom Kidney Cancer Drugs Market Share (%), By Cancer Type, 2018-2032F
  • Figure 60. United Kingdom Kidney Cancer Drugs Market Share (%), By Therapy, 2018-2032F
  • Figure 61. United Kingdom Kidney Cancer Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 62. United Kingdom Kidney Cancer Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 63. United Kingdom Kidney Cancer Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 64. Russia Kidney Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 65. Russia Kidney Cancer Drugs Market Share (%), By Cancer Type, 2018-2032F
  • Figure 66. Russia Kidney Cancer Drugs Market Share (%), By Therapy, 2018-2032F
  • Figure 67. Russia Kidney Cancer Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 68. Russia Kidney Cancer Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 69. Russia Kidney Cancer Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 70. Netherlands Kidney Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 71. Netherlands Kidney Cancer Drugs Market Share (%), By Cancer Type, 2018-2032F
  • Figure 72. Netherlands Kidney Cancer Drugs Market Share (%), By Therapy, 2018-2032F
  • Figure 73. Netherlands Kidney Cancer Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 74. Netherlands Kidney Cancer Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 75. Netherlands Kidney Cancer Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 76. Spain Kidney Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 77. Spain Kidney Cancer Drugs Market Share (%), By Cancer Type, 2018-2032F
  • Figure 78. Spain Kidney Cancer Drugs Market Share (%), By Therapy, 2018-2032F
  • Figure 79. Spain Kidney Cancer Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 80. Spain Kidney Cancer Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 81. Spain Kidney Cancer Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 82. Turkey Kidney Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 83. Turkey Kidney Cancer Drugs Market Share (%), By Cancer Type, 2018-2032F
  • Figure 84. Turkey Kidney Cancer Drugs Market Share (%), By Therapy, 2018-2032F
  • Figure 85. Turkey Kidney Cancer Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 86. Turkey Kidney Cancer Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 87. Turkey Kidney Cancer Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 88. Poland Kidney Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 89. Poland Kidney Cancer Drugs Market Share (%), By Cancer Type, 2018-2032F
  • Figure 90. Poland Kidney Cancer Drugs Market Share (%), By Therapy, 2018-2032F
  • Figure 91. Poland Kidney Cancer Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 92. Poland Kidney Cancer Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 93. Poland Kidney Cancer Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 94. South America Kidney Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 95. South America Kidney Cancer Drugs Market Share (%), By Cancer Type, 2018-2032F
  • Figure 96. South America Kidney Cancer Drugs Market Share (%), By Therapy, 2018-2032F
  • Figure 97. South America Kidney Cancer Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 98. South America Kidney Cancer Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 99. South America Kidney Cancer Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 100. South America Kidney Cancer Drugs Market Share (%), By Country, 2018-2032F
  • Figure 101. Brazil Kidney Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 102. Brazil Kidney Cancer Drugs Market Share (%), By Cancer Type, 2018-2032F
  • Figure 103. Brazil Kidney Cancer Drugs Market Share (%), By Therapy, 2018-2032F
  • Figure 104. Brazil Kidney Cancer Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 105. Brazil Kidney Cancer Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 106. Brazil Kidney Cancer Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 107. Argentina Kidney Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 108. Argentina Kidney Cancer Drugs Market Share (%), By Cancer Type, 2018-2032F
  • Figure 109. Argentina Kidney Cancer Drugs Market Share (%), By Therapy, 2018-2032F
  • Figure 110. Argentina Kidney Cancer Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 111. Argentina Kidney Cancer Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 112. Argentina Kidney Cancer Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 113. Asia-Pacific Kidney Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 114. Asia-Pacific Kidney Cancer Drugs Market Share (%), By Cancer Type, 2018-2032F
  • Figure 115. Asia-Pacific Kidney Cancer Drugs Market Share (%), By Therapy, 2018-2032F
  • Figure 116. Asia-Pacific Kidney Cancer Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 117. Asia-Pacific Kidney Cancer Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 118. Asia-Pacific Kidney Cancer Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 119. Asia-Pacific Kidney Cancer Drugs Market Share (%), By Country, 2018-2032F
  • Figure 120. India Kidney Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 121. India Kidney Cancer Drugs Market Share (%), By Cancer Type, 2018-2032F
  • Figure 122. India Kidney Cancer Drugs Market Share (%), By Therapy, 2018-2032F
  • Figure 123. India Kidney Cancer Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 124. India Kidney Cancer Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 125. India Kidney Cancer Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 126. China Kidney Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 127. China Kidney Cancer Drugs Market Share (%), By Cancer Type, 2018-2032F
  • Figure 128. China Kidney Cancer Drugs Market Share (%), By Therapy, 2018-2032F
  • Figure 129. China Kidney Cancer Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 130. China Kidney Cancer Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 131. China Kidney Cancer Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 132. Japan Kidney Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 133. Japan Kidney Cancer Drugs Market Share (%), By Cancer Type, 2018-2032F
  • Figure 134. Japan Kidney Cancer Drugs Market Share (%), By Therapy, 2018-2032F
  • Figure 135. Japan Kidney Cancer Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 136. Japan Kidney Cancer Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 137. Japan Kidney Cancer Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 138. Australia Kidney Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 139. Australia Kidney Cancer Drugs Market Share (%), By Cancer Type, 2018-2032F
  • Figure 140. Australia Kidney Cancer Drugs Market Share (%), By Therapy, 2018-2032F
  • Figure 141. Australia Kidney Cancer Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 142. Australia Kidney Cancer Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 143. Australia Kidney Cancer Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 144. Vietnam Kidney Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 145. Vietnam Kidney Cancer Drugs Market Share (%), By Cancer Type, 2018-2032F
  • Figure 146. Vietnam Kidney Cancer Drugs Market Share (%), By Therapy, 2018-2032F
  • Figure 147. Vietnam Kidney Cancer Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 148. Vietnam Kidney Cancer Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 149. Vietnam Kidney Cancer Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 150. South Korea Kidney Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 151. South Korea Kidney Cancer Drugs Market Share (%), By Cancer Type, 2018-2032F
  • Figure 152. South Korea Kidney Cancer Drugs Market Share (%), By Therapy, 2018-2032F
  • Figure 153. South Korea Kidney Cancer Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 154. South Korea Kidney Cancer Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 155. South Korea Kidney Cancer Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 156. Indonesia Kidney Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 157. Indonesia Kidney Cancer Drugs Market Share (%), By Cancer Type, 2018-2032F
  • Figure 158. Indonesia Kidney Cancer Drugs Market Share (%), By Therapy, 2018-2032F
  • Figure 159. Indonesia Kidney Cancer Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 160. Indonesia Kidney Cancer Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 161. Indonesia Kidney Cancer Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 162. Philippines Kidney Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 163. Philippines Kidney Cancer Drugs Market Share (%), By Cancer Type, 2018-2032F
  • Figure 164. Philippines Kidney Cancer Drugs Market Share (%), By Therapy, 2018-2032F
  • Figure 165. Philippines Kidney Cancer Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 166. Philippines Kidney Cancer Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 167. Philippines Kidney Cancer Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 168. Middle East & Africa Kidney Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 169. Middle East & Africa Kidney Cancer Drugs Market Share (%), By Cancer Type, 2018-2032F
  • Figure 170. Middle East & Africa Kidney Cancer Drugs Market Share (%), By Therapy, 2018-2032F
  • Figure 171. Middle East & Africa Kidney Cancer Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 172. Middle East & Africa Kidney Cancer Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 173. Middle East & Africa Kidney Cancer Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 174. Middle East & Africa Kidney Cancer Drugs Market Share (%), By Country, 2018-2032F
  • Figure 175. Saudi Arabia Kidney Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 176. Saudi Arabia Kidney Cancer Drugs Market Share (%), By Cancer Type, 2018-2032F
  • Figure 177. Saudi Arabia Kidney Cancer Drugs Market Share (%), By Therapy, 2018-2032F
  • Figure 178. Saudi Arabia Kidney Cancer Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 179. Saudi Arabia Kidney Cancer Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 180. Saudi Arabia Kidney Cancer Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 181. UAE Kidney Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 182. UAE Kidney Cancer Drugs Market Share (%), By Cancer Type, 2018-2032F
  • Figure 183. UAE Kidney Cancer Drugs Market Share (%), By Therapy, 2018-2032F
  • Figure 184. UAE Kidney Cancer Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 185. UAE Kidney Cancer Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 186. UAE Kidney Cancer Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 187. South Africa Kidney Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 188. South Africa Kidney Cancer Drugs Market Share (%), By Cancer Type, 2018-2032F
  • Figure 189. South Africa Kidney Cancer Drugs Market Share (%), By Therapy, 2018-2032F
  • Figure 190. South Africa Kidney Cancer Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 191. South Africa Kidney Cancer Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 192. South Africa Kidney Cancer Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 193. By Cancer Type Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 194. By Therapy Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 195. By Drug Class Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 196. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 197. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 198. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2024